Last checked at 29 Dec 2020 12:59
29 December 2020
SkinBioTherapeutics plc
Results of AGM
SkinBioTherapeutics plc's (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the Company's Registrar are set out below:
Resolution | For & Discretionary | Against | Withheld | |||
Number of votes | % | Number of votes | % | Number of votes | ||
01 | Ordinary resolution to receive and adopt the 2020 Financial Statements | 56,163,552 |
100.00%
| Nil | 0.00% | Nil |
02 | Ordinary resolution to re-appoint Jeffreys Henry as auditors | 56,163,552 |
100.00%
| Nil | 0.00% | Nil |
03 | Ordinary resolution to re-elect Stuart Ashman as a director | 56,140,652 | 99.96% | 22,900 | 0.04% | Nil |
04 | Ordinary resolution to re-elect Martin Hunt as a director | 56,140,652 | 99.96% | 22,900 | 0.04% | Nil |
05 | Ordinary resolution to re-elect Dr Cathy Prescott as a director | 56,163,552 |
100.00%
| Nil | 0.00% | Nil |
06 | Ordinary resolution to re-elect Doug Quinn as a director | 56,140,652 | 99.96% | 22,900 | 0.04% | Nil |
07 | Ordinary resolution to authorise the directors to allot shares | 56,107,097 | 99.90% | 22,900 | 0.04% | 33,555 |
08 | Special resolution to authorise the directors to disapply pre-emption rights | 55,896,449 | 99.52% | 37,294 | 0.07% | 229,809 |
09 | Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment | 55,897,801 | 99.53% | 35,942 | 0.06% | 229,809 |
For more information please contact:
SkinBioTherapeutics plc | Tel: +44 (0) 161 468 2760 |
Stuart Ashman, CEO Doug Quinn, CFO | |
Cenkos Securities plc (Nominated Adviser & Broker) | Tel: +44 (0) 20 7397 8900 |
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales) | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis | SkinBio@instinctif.com
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:www.skinbiotherapeutics.com.